FDA Approves Revolution Medicines' Rasonque for Pancreatic Cancer
The FDA has approved Rasonque, a new drug offering hope for advanced pancreatic cancer patients.
The Food and Drug Administration (FDA) has granted approval for Rasonque, a novel pancreatic cancer drug developed by Revolution Medicines. This approval marks a significant advancement in the treatment of one of the deadliest forms of cancer.
Extended Survival Rates in Trials
Rasonque, also known as daraxonrasib, has shown promising results in clinical trials. In a late-stage trial involving 500 patients, those treated with Rasonque in combination with standard chemotherapy lived an average of 13.2 months, nearly double the survival time of patients receiving chemotherapy alone. This breakthrough offers a new avenue of hope for patients with advanced pancreatic cancer who have exhausted other treatment options.
Targeting the KRAS Mutation
The drug specifically targets a mutation in the KRAS gene, which is present in nearly all pancreatic cancers. This mutation causes cells to grow uncontrollably by keeping the gene's 'on' switch activated. Rasonque is administered as a daily pill and is the first successful attempt to target this mutation effectively, a feat that has eluded scientists for years.
Expert Reactions and Side Effects
Dr. Rachna Shroff, chief of the division of hematology and oncology at the University of Arizona Cancer Center, expressed her enthusiasm, describing the drug as a 'game changer' for treating pancreatic cancer. While the drug shows great promise, it comes with side effects such as a blistering rash, mouth sores, vomiting, and diarrhea. Former Senator Ben Sasse, who participated in the clinical trial, characterized the rash as 'nuclear' during a podcast interview.
Future Prospects and Availability
Channing Der, a pharmacologist at the University of North Carolina at Chapel Hill, hailed the FDA's approval as a 'monumental moment' in pancreatic cancer treatment. With pancreatic cancer being the third leading cause of cancer death in the U.S., this development could pave the way for further advancements in the field. According to the American Cancer Society, over 67,000 Americans are expected to be diagnosed with pancreatic cancer this year, a disease notoriously difficult to detect early. Revolution Medicines has already provided the drug to over 2,000 patients through an expanded access program initiated in May. Pricing details for Rasonque have yet to be disclosed.